Download PDF
CC BY 4.0 · Eur J Dent 2023; 17(04): 1215-1220
DOI: 10.1055/s-0043-1761191
Original Article

Differential Expression Profile of Salivary oncomiRNAs among Smokeless Tobacco Users

Natheer H. AL-Rawi 
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
2   Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates
,
Zuha Rizvi
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
2   Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates
,
Sarra Mkadmi
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Rawan Abu Kou
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Neibal Elmabrouk
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Mohammad S. Alrashdan
1   Department of Oral & Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Aghila Rani Koippallil Gopalakrishnan
2   Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates
› Author Affiliations Funding This work was supported by the University of Sharjah [grant number 2101100139].
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective The aim of this study was to evaluate the expression of selected salivary oncomiRNAs among smokeless tobacco users and nonsmokers.

Materials and Methods Twenty-five subjects with chronic smokeless tobacco habit (> 1 year) and 25 nonsmokers were selected for this study. MicroRNA was extracted from saliva samples using the miRNeasy Kit (Qiagen, Hilden, Germany). The forward primers used in the reactions include hsa-miR-21-5p, hsa-miR-146a-3p, hsa-miR-155-3p, and hsa-miR-199a-3p. Relative expression of miRNAs was calculated using the 2-ΔΔCt method. Fold change is calculated by raising 2 to the power of the negative ΔΔCT value.

Statistical Analysis Statistical analysis was carried out using GraphPad Prism 5 software. A p-value less than 0.05 was considered statistically significant.

Results The four tested miRNAs were found overexpressed in saliva of subjects with smokeless tobacco habit when compared with saliva from nontobacco users. miR-21 expression was 3.74 ± 2.26 folds higher among subjects with smokeless tobacco habit compared to nontobacco users (p < 0.01). The expression for miR-146a (5.56 ± 8.3 folds; p < 0.05), miR-155 (8.06 ± 23.4 folds; p < 0.0001) and miR-199a (14.39 ± 30.3 folds; p < 0.05) was significantly higher among subjects with smokeless tobacco habit.

Conclusion Smokeless tobacco leads to salivary overexpression of the miRs 21, 146a, 155, and 199a. Monitoring the levels of these four oncomiRs may provide insight about the future development of oral squamous cell carcinoma, especially in patients with smokeless tobacco habits.

Keywords

smokeless tobacco - miR-21 - miR-146a - miR-155 - miR-199a - oral cancer

Supplementary Material



Publication History

Article published online:
22 February 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Quadri MFA, Tadakamadla SK, John T. Smokeless tobacco and oral cancer in the Middle East and North Africa: a systematic review and meta-analysis. Tob Induc Dis 2019; 17: 56
    PubMedGoogle Scholar
  • 2 Alsharif MT, Alsharif AT, Krsoum MA. et al. Trend analysis of head and neck neoplasms between 2012-2018 in patients residing in Al-Madinah, Saudi Arabia: a retrospective study. Eur J Dent 2021; 15 (03) 509-514
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Alqahtani WS, Almufareh NA, Al-Johani HA. et al. Oral and oropharyngeal cancers and possible risk factors across Gulf Cooperation Council Countries: a systematic review. World J Oncol 2020; 11 (04) 173-181
    CrossrefPubMedGoogle Scholar
  • 4 National Cancer Institute and Centers for Disease Control and Prevention. Smokeless Tobacco and Public Health: A Global Perspective. Bethesda, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Institutes of Health, National Cancer Institute. NIH Publication No. 14-7983; 2014
    PubMedGoogle Scholar
  • 5 Saleem S, Azhar A, Hameed A. et al. P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan. Oral Oncol 2013; 49 (08) 818-823
    CrossrefPubMedGoogle Scholar
  • 6 Asthana S, Labani S, Kailash U, Sinha DN, Mehrotra R. Association of smokeless tobacco use and oral cancer: a systematic global review and meta-analysis. Nicotine Tob Res 2019; 21 (09) 1162-1171
    CrossrefPubMedGoogle Scholar
  • 7 Farazi TA, Juranek SA, Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development 2008; 135 (07) 1201-1214
    CrossrefPubMedGoogle Scholar
  • 8 Lu J, Getz G, Miska EA. et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834-838
    CrossrefPubMedGoogle Scholar
  • 9 Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. Int J Cancer 2013; 132 (12) 2884-2893
    CrossrefPubMedGoogle Scholar
  • 10 Felekkis K, Touvana E, Stefanou Ch, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010; 14 (04) 236-240
    PubMedGoogle Scholar
  • 11 Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol 2011; 47 (04) 282-287
    CrossrefPubMedGoogle Scholar
  • 12 Wong DT. Salivary diagnostics for oral cancer. J Calif Dent Assoc 2006; 34 (04) 303-308
    CrossrefPubMedGoogle Scholar
  • 13 Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 2006; 137 (03) 313-321
    CrossrefPubMedGoogle Scholar
  • 14 Hema Shree K, Ramani P, Sherlin H. et al. Saliva as a diagnostic tool in oral squamous cell carcinoma - a systematic review with meta analysis. Pathol Oncol Res 2019; 25 (02) 447-453
    CrossrefPubMedGoogle Scholar
  • 15 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monogr Eval Carcinog Risks Hum 2007; 89: 1-592
    PubMedGoogle Scholar
  • 16 Al Rawi N, Elmabrouk N, Abu Kou R, Mkadmi S, Rizvi Z, Hamdoon Z. The role of differentially expressed salivary microRNA in oral squamous cell carcinoma. A systematic review. Arch Oral Biol 2021; 125: 105108
    CrossrefPubMedGoogle Scholar
  • 17 Al-Rawi NH, Al-Marzooq F, Al-Nuaimi AS, Hachim MY, Hamoudi R. Salivary microRNA 155, 146a/b and 203: a pilot study for potentially non-invasive diagnostic biomarkers of periodontitis and diabetes mellitus. PLoS One 2020; 15 (08) e0237004
    CrossrefPubMedGoogle Scholar
  • 18 Zeng Q, Tao X, Huang F. et al. Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6/cyclin D2. Int J Mol Med 2016; 37 (05) 1274-1280
    CrossrefPubMedGoogle Scholar
  • 19 Momi N, Kaur S, Rachagani S, Ganti AK, Batra SK. Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med 2014; 20 (01) 36-47
    CrossrefPubMedGoogle Scholar
  • 20 Shiiba M, Uzawa K, Tanzawa H. MicroRNAs in head and neck squamous cell carcinoma (HNSCC) and oral squamous cell carcinoma (OSCC). Cancers (Basel) 2010; 2 (02) 653-669
    CrossrefPubMedGoogle Scholar
  • 21 Vahabi M, Blandino G, Di Agostino S. MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. Transl Cancer Res 2021; 10 (06) 3090-3110
    CrossrefPubMedGoogle Scholar
  • 22 Mahmood N, Hanif M, Ahmed A. et al. Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma. Pak J Med Sci 2019; 35 (05) 1408-1412
    CrossrefPubMedGoogle Scholar
  • 23 Hu Q, Song J, Ding B, Cui Y, Liang J, Han S. miR-146a promotes cervical cancer cell viability via targeting IRAK1 and TRAF6. Oncol Rep 2018; 39 (06) 3015-3024
    PubMedGoogle Scholar
  • 24 Hung PS, Liu CJ, Chou CS. et al. miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. PLoS One 2013; 8 (11) e79926
    CrossrefPubMedGoogle Scholar
  • 25 Iacona JR, Lutz CS. miR-146a-5p: expression, regulation, and functions in cancer. Wiley Interdiscip Rev RNA 2019; 10 (04) e1533
    CrossrefPubMedGoogle Scholar
  • 26 Wei D, Wang W, Shen B. et al. MicroRNA–199a–5p suppresses migration and invasion in oral squamous cell carcinoma through inhibiting the EMT–related transcription factor SOX4. Int J Mol Med 2019; 44 (01) 185-195
    PubMedGoogle Scholar
  • 27 Yang Z, Ren F, Liu C. et al. dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genomics 2010; 11 (Suppl. 04) S5
    CrossrefPubMedGoogle Scholar
  • 28 Lubov J, Maschietto M, Ibrahim I. et al. Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. Oncotarget 2017; 8 (33) 55511-55524
    CrossrefPubMedGoogle Scholar
  • 29 Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A. et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 2020; 20: 409-420
    CrossrefPubMedGoogle Scholar
  • 30 Tang C, Wang J, Wei Q. et al. Tropomyosin-1 promotes cancer cell apoptosis via the p53-mediated mitochondrial pathway in renal cell carcinoma. Oncol Lett 2018; 15 (05) 7060-7068
    PubMedGoogle Scholar
  • 31 Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep 2016; 5 (04) 395-402
    CrossrefPubMedGoogle Scholar
  • 32 DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012; 246 (01) 379-400
    CrossrefPubMedGoogle Scholar
  • 33 Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009; 28 (Suppl. 01) S32-S37
    CrossrefPubMedGoogle Scholar
  • 34 Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) 2011; 4 (08) 1149-1157
    CrossrefPubMedGoogle Scholar
  • 35 Miyazono K, Ehata S, Koinuma D. Tumor-promoting functions of transforming growth factor-β in progression of cancer. Ups J Med Sci 2012; 117 (02) 143-152
    CrossrefPubMedGoogle Scholar
  • 36 Liu X, Liu B, Li R. et al. miR-146a-5p Plays an Oncogenic Role in NSCLC via Suppression of TRAF6. Front Cell Dev Biol 2020; 8: 847
    CrossrefPubMedGoogle Scholar
  • 37 Dent AL, Vasanwala FH, Toney LM. Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol 2002; 41 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 38 Nazari-Jahantigh M, Wei Y, Noels H. et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012; 122 (11) 4190-4202
    CrossrefPubMedGoogle Scholar
  • 39 Mahesh G, Biswas R. MicroRNA-155: a master regulator of inflammation. J Interferon Cytokine Res 2019; 39 (06) 321-330
    CrossrefPubMedGoogle Scholar
  • 40 Hu J, Huang S, Liu X, Zhang Y, Wei S, Hu X. miR-155: an important role in inflammation response. J Immunol Res 2022; 2022: 7437281
    PubMedGoogle Scholar